Hengrui Presents 64 Oncology Studies at ESMO Congress in Madrid
Chinese pharmaceutical firm Hengrui showcased its latest oncology research and clinical trial data at the 2026 ESMO Congress.
Hengrui delivered 64 research presentations at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid. The scale of the data presented underscores the company’s efforts to transition from a China-focused pharmaceutical firm to an internationally recognized player in the oncology sector.
The presentations highlighted various clinical approaches to cancer treatment, reflecting the company’s ongoing investment in research and development. By sharing these findings with an international audience of oncologists and industry stakeholders, Hengrui aims to secure its position within the global medical research landscape.
As the pharmaceutical sector faces increased competition, Hengrui is leveraging high-profile medical congresses to validate its clinical trials and broaden its reach. The company continues to prioritize international collaboration as a core component of its growth strategy.